FDA In Brief > FDA In Brief: FDA adds four tropical diseases to priority review voucher program to encourage drug development in areas of unmet need

FDA In Brief > FDA In Brief: FDA adds four tropical diseases to priority review voucher program to encourage drug development in areas of unmet need

FDA adds four tropical diseases to priority review voucher program to encourage drug development in areas of unmet need

FDA announced the addition of Lassa fever, chikungunya virus disease, rabies, and cryptococcal meningitis to the list of tropical diseases.  Applicants who submit applications for drug or biological products to prevent or treat these diseases may qualify for a tropical disease priority review voucher (PRV). A tropical disease PRV can be used to obtain priority review of a subsequent drug application that does not itself qualify for priority review. Related: MCM priority review voucher program